![1]()
News
Subclinical myocarditis found in some athletes post COVID
June 2, 2021
A study that evaluated college athletes recently infected with COVID-19 with comprehensive cardiac testing, including MRI, found a small percentage had myocarditis despite being asymptomatic.
![1]()
News
Single subcutaneous shot offers fast, potent platelet inhibition in STEMI
June 1, 2021
The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.
![1]()
News
Significant reduction of alcohol intake reduced AFib burden and recurrence
June 1, 2021
In patients with symptomatic paroxysmal or persistent AFib who report alcohol consumption of 10 or more standard drinks per week, how does reducing alcohol intake affect AFib outcomes?
![1]()
News
New AHA/ASA guideline on secondary stroke prevention
May 27, 2021
Identifying the cause of a first stroke or transient ischemic attack is key to developing strategies to prevent repeat events, the AHA/ASA says in an updated clinical practice guideline.
News
AHA reassures myocarditis rare after COVID vaccination, benefits overwhelm risks
May 24, 2021
As CDC investigates rare, mostly mild cases of myocarditis in adolescents and young adults given the Pfizer or Moderna vaccine, AHA emphasizes their effectiveness and strong safety record.
![1]()
News
GALACTIC-HF: Novel drug most effective in sickest HFrEF patients
May 24, 2021
In GALACTIC-HF trial, the greatest relative benefit of omecamtiv mecarbil was in the sickest HFrEF patients.
![1]()
News
Sotagliflozin’s HFpEF benefit confirmed by new analyses
May 24, 2021
A meta-analysis of two pivotal trials for the SGLT1/2 inhibitor sotagliflozin prospectively documents a HFpEF benefit.
![1]()
News
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
May 18, 2021
A prespecified, exploratory analysis from the FIDELIO-DKD trial showed that the nonsteroidal MRA finerenone significantly cut new-onset AFib.
![1]()
News
Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit
May 18, 2021
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close.
![1]()
News
PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
May 15, 2021
When treating patients with no history of heart failure within days of an acute myocardial infarction, sacubitril/valsartan showed safety but no clear superiority to ramipril.
